VBI (4170.TWO)
- Previous Close
13.10 - Open
12.50 - Bid 12.45 x --
- Ask 13.10 x --
- Day's Range
12.50 - 12.80 - 52 Week Range
10.40 - 21.10 - Volume
11,001 - Avg. Volume
30,032 - Market Cap (intraday)
569.028M - Beta (5Y Monthly) -0.05
- PE Ratio (TTM)
-- - EPS (TTM)
-0.92 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Vectorite Biomedical Inc. engages in the research and development of biotechnology in Taiwan and internationally. It offers cell preparation product manufacturing; and collection, processing, and storage management of immune cells. The company's cell preparation products are used in the field of infectious diseases and inflammation, cancer, and tumor diseases. Vectorite Biomedical Inc. was founded in 1993 and is based in New Taipei City, Taiwan.
www.vectorite.com.twRecent News: 4170.TWO
View MorePerformance Overview: 4170.TWO
Trailing total returns as of 6/13/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4170.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4170.TWO
View MoreValuation Measures
Market Cap
547.14M
Enterprise Value
362.24M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.42
Price/Book (mrq)
1.41
Enterprise Value/Revenue
6.27
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-69.33%
Return on Assets (ttm)
-3.75%
Return on Equity (ttm)
-9.77%
Revenue (ttm)
57.77M
Net Income Avi to Common (ttm)
-40.05M
Diluted EPS (ttm)
-0.92
Balance Sheet and Cash Flow
Total Cash (mrq)
184.9M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-12.32M